LONDON, UK, March 11, 2026
George Medicines, a late-stage biopharmaceutical company focused on cardiometabolic diseases, has announced an exclusive licensing and supply agreement with Ahngook Pharmaceutical Co. Ltd. to commercialize its innovative hypertension treatment GMRx2 in South Korea. The agreement grants Ahngook Pharmaceutical exclusive rights to seek regulatory approval and commercialize the therapy in Korea, while George Medicines will receive an upfront licensing payment along with potential regulatory and commercial milestone payments and future royalties on sales. The deal represents the fifth major international licensing agreement for GMRx2, highlighting the company’s growing global commercialization strategy to improve cardiovascular care worldwide.
The medicine is an innovative single-pill triple combination therapy containing telmisartan, amlodipine, and indapamide, designed to deliver early and effective blood pressure reduction through multiple mechanisms while maintaining the safety profile of well-established antihypertensive medications. The collaboration reflects increasing demand for combination therapies that simplify treatment regimens and improve patient adherence in hypertension management, a condition that remains one of the leading causes of cardiovascular disease and premature mortality globally.
Innovative Triple Combination Therapy Targets Hypertension
The investigational medicine GMRx2 represents a new approach to treating hypertension using a single-pill combination of three established medications, each targeting different biological pathways involved in blood pressure regulation. The therapy combines telmisartan, an angiotensin II receptor blocker; amlodipine, a calcium channel blocker; and indapamide, a thiazide-like diuretic, creating a multi-mechanism strategy designed to deliver stronger blood pressure reduction earlier in the treatment pathway.
This approach aims to address challenges in current hypertension management where many patients require multiple medications but often struggle with adherence to complex treatment regimens. By integrating three therapies into one daily tablet, GMRx2 may help improve treatment compliance and achieve more effective blood pressure control, ultimately reducing the risk of heart attack, stroke, and other cardiovascular complications.
Advertisement
The therapy is available in three dosage strengths, enabling physicians to tailor treatment according to patient needs while maintaining a favorable safety profile supported by well-established medications.
Clinical Evidence Supports Cardiovascular Benefits
Development of GMRx2 has been supported by an extensive clinical program, including two pivotal Phase III trials published in leading medical journals, which demonstrated significant reductions in blood pressure and improved blood pressure control compared with dual therapy and placebo. The studies also reported good tolerability and no increase in treatment discontinuation due to adverse events, supporting the therapy’s potential as a safe and effective option for long-term hypertension management.
Additional research has been conducted in the VERONICA clinical trial in Nigeria, which compared the triple combination therapy with standard treatment protocols and reported superior blood pressure reduction among patients receiving GMRx2. Beyond hypertension treatment, the medicine is currently being evaluated in a global clinical trial investigating its potential to reduce stroke risk in patients with a history of intracerebral hemorrhage, the most severe form of stroke. These studies highlight the potential of **multi-mechanism combination therapies to improve cardiovascular outcomes while simplifying treatment strategies for patients and physicians.
Global Commercialization Strategy Expands
The partnership with Ahngook Pharmaceutical, a leading Korean pharmaceutical company, represents a key milestone in George Medicines’ international commercialization strategy for GMRx2. Under the agreement, Ahngook will be responsible for seeking regulatory approval in South Korea and leading commercial distribution, while George Medicines will provide product supply and ongoing support.
This partnership builds on a growing network of global collaborations established by the company, including licensing agreements with pharmaceutical partners across North America, Latin America, and Southeast Asia. The strategy aims to accelerate global access to innovative cardiovascular medicines while leveraging regional expertise for regulatory approval and market adoption. Company leadership emphasized that hypertension and other cardiometabolic disorders remain among the largest global health challenges, affecting hundreds of millions of people worldwide.
By expanding access to therapies like GMRx2 through international partnerships, George Medicines hopes to improve treatment outcomes and reduce the global burden of cardiovascular disease through innovative pharmaceutical solutions.
Source: George Medicines press release
